Sponsor: Alzheimer’s Drug Discovery Foundation
Letter of Intent:
September 30, 2022
Invited Full Proposal:
December 2, 2022
The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use. Award Amount:
Up to $600,000 based on stage and scope of research.